101862-47-9 Usage
Uses
Used in Pharmaceutical Industry:
(2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine is used as a key intermediate in the synthesis of pharmaceutical compounds, particularly for the development of zinc and copper complexes. These complexes have potential applications in the treatment of various diseases and disorders due to their unique chemical properties and interactions with biological systems.
Used in Chemical Synthesis:
In the field of chemical synthesis, (2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine serves as a valuable building block for the creation of novel molecules with potential applications in various industries, such as agriculture, materials science, and environmental science. Its unique structure allows for the development of new compounds with improved properties and functionalities.
Used in Research and Development:
(2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine is also utilized in research and development for the study of its chemical properties, reactivity, and potential applications in various fields. (2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine can be used to explore new reaction pathways, develop innovative synthetic methods, and investigate its interactions with other molecules and biological systems.
Check Digit Verification of cas no
The CAS Registry Mumber 101862-47-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,8,6 and 2 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 101862-47:
(8*1)+(7*0)+(6*1)+(5*8)+(4*6)+(3*2)+(2*4)+(1*7)=99
99 % 10 = 9
So 101862-47-9 is a valid CAS Registry Number.
101862-47-9Relevant academic research and scientific papers
METHOD FOR SCREENING SUBSTANCE CAPABLE OF INHIBITING ABNORMAL SPLICING CAUSATIVE OF ONSET OR PROGRESS OF DISEASE
-
Paragraph 0193; 0194; 0195, (2016/06/28)
A compound and a pharmaceutical composition for disease associated with an abnormal splice variant, use of the compound and the pharmaceutical composition, or a screening method of the compound and the pharmaceutical composition are provided. One or more embodiments disclose a compound expressed by the following formula (I) or (I′) or prodrugs or pharmaceutically acceptable salts thereof. Another one or more embodiments disclose a screening method using a DNA construct that is fused, arranged, or constructed so as to express different reporter genes for a wild-type splice variant and an abnormal splice variant that contributes to the development or progression of disease;
